Myomo, Inc. (MYO) Q4 2025 Earnings Call Transcript

Myomo hosted its Q4 and full-year 2025 earnings call on March 9, 2026, led by CEO Paul Gudonis and CFO Dave Henry with participation from multiple sell-side analysts. The provided excerpt is limited to introductory remarks and a standard forward-looking statements disclaimer and does not include any financial results, metrics, or guidance. Because no financial data or guidance was included in this excerpt, there is minimal near-term market-moving information.

Analysis

Myomo’s core optionality lives in durable reimbursement and data-driven differentiation rather than hardware alone. If management can convert pilot outcomes into Local or National Medicare coverage within 6–18 months, revenue becomes less lumpy and gross margins can expand meaningfully as device unit economics scale — think 700–1,000 bps of gross-margin leverage as fixed R&D and onboarding costs dilute. The real second-order beneficiary is large DME consolidators and tele-rehab platforms that embed Myomo as a recurring-service line; these partners can shorten sales cycles but will demand margin concessions and volume commitments that compress short-term ASPs.

Principal downside comes from payor retrenchment and supply-chain pinch points for micro-actuators/batteries: a single multi-quarter component shortage or an adverse LCD decision could claw back >30–40% of modeled revenue over 12–24 months given concentrated payor channels. Near-term (days–weeks) risk is binary event volatility around guidance updates or pilot announcements; medium-term (3–12 months) risk centers on contract cadence with a handful of health systems. Conversely, the under-appreciated upside is non-device revenue—remote monitoring, data licensing and software updates—which could convert a hardware sale into a 3–5 year annuity and re-rate valuation multiples if executed.

Consensus tends to treat Myomo as a pure-capex device play and underweights service-stickiness and payor evidence generation. That makes event-driven, option-defined exposure attractive: limited downside premium for asymmetric upside on positive coverage/pilot readouts. Execution remains the primary earnings lever — any significant wholesale adoption by a large DME or a favorable Medicare decision within 12 months is a clear re-rating catalyst.

Key Decisions for Investors

• Buy MYO equity on a pullback of 15–25% from current levels or on confirmation of a multi-system DME contract; 6–12 month horizon; target 80–120% upside if adoption accelerates, initial stop-loss 30% to cap downside from execution risk.
• Buy 12-month MYO call spreads (long ATM, sell 1.5x strike) sized to risk no more than 2–3% of portfolio — asymmetric payoff if Medicare/LCD or large health-system pilots convert; target 2.5x on premium, max loss = net premium.
• Pair trade: long MYO / short EKSO (EKSO) equal notional for 6–12 months to isolate company-specific execution; expect MYO to outperform if payor evidence and DME integrations scale; tail risk is sector-wide robotics re-rating.
• Event hedge: buy 3-month OTM put spreads on MYO ahead of any announced supply issues or adverse guidance windows (limit cost to <1% portfolio). This protects against >30% downside from binary negative catalysts while keeping carry low.